Cartilage-homing peptide conjugates and methods of use thereof

A peptide active agent conjugate, the peptide active agent conjugate comprising:

• a) a peptide comprising a sequence that has at least 85% sequence identity to SEQ ID NO:
• 396 or a fragment thereof comprising at least 18 amino acid residues that has at least 85% sequence identity to SEQ ID NO:
• 396;
• and
• b) an active agent, wherein the active agent is desciclesonide, kineret, a j anus kinase (JAK) inhibitor, tofacitinib, dasatinib, flunisolide, an interleukin-1 (IL-1) inhibitor, an interleukin-1 (IL-1) receptor antagonist, an interleukin-12 (IL-12) antagonist, fibroblast growth factor 18 (FGF-18), insulin-like growth factor 1 (IGF-1), transforming growth factor beta (TFG-ß), a cathepsin K inhibitor, an NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome drug, or MCC950.

A method of imaging an organ or body region of a subject comprising administering to the subject a peptide active agent conjugate comprising:

• a) a peptide comprising a sequence that has at least 85% sequence identity to SEQ ID NO:
• 396 or a fragment thereof comprising at least 18 amino acid residues that has at least 85% sequence identity to SEQ ID NO:
• 396;
• b) an active agent, wherein the active agent is desciclesonide, kineret, a j anus kinase (JAK) inhibitor, tofacitinib, dasatinib, flunisolide, an interleukin-1 (IL-1) inhibitor, an interleukin-1 (IL-1) receptor antagonist, an interleukin-12 (IL-12) antagonist, fibroblast growth factor 18 (FGF-18), insulin-like growth factor 1 (IGF-1), transforming growth factor beta (TFG-ß), a cathepsin K inhibitor, an NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome drug, or MCC950;
• and
• c) a detectable agent.

A method of treating a cartilage or kidney disorder in a subject comprising administering to the subject a peptide active agent conjugate comprising:

• a) a peptide comprising a sequence that has at least 85% sequence identity to SEQ ID NO:
• 396 or a fragment thereof comprising at least 18 amino acid residues that has at least 85% sequence identity to SEQ ID NO:
• 396;
• and
• b) an active agent, wherein the active agent is desciclesonide, kineret, a j anus kinase (JAK) inhibitor, tofacitinib, dasatinib, flunisolide, an interleukin-1 (IL-1) inhibitor, an interleukin-1 (IL-1) receptor antagonist, an interleukin-12 (IL-12) antagonist, fibroblast growth factor 18 (FGF-18), insulin-like growth factor 1 (IGF-1), transforming growth factor beta (TFG-ß), a cathepsin K inhibitor, an NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome drug, or MCC950.